258 related articles for article (PubMed ID: 31896087)
1. Adamantinomatous craniopharyngioma: moving toward targeted therapies.
Hengartner AC; Prince E; Vijmasi T; Hankinson TC
Neurosurg Focus; 2020 Jan; 48(1):E7. PubMed ID: 31896087
[TBL] [Abstract][Full Text] [Related]
2. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
[TBL] [Abstract][Full Text] [Related]
3. Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics.
Robinson LC; Santagata S; Hankinson TC
Neurosurg Focus; 2016 Dec; 41(6):E3. PubMed ID: 27903126
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice.
Apps JR; Martinez-Barbera JP
Neurosurg Focus; 2016 Dec; 41(6):E4. PubMed ID: 27903120
[TBL] [Abstract][Full Text] [Related]
5. Sonic Hedgehog pathway is upregulated in adamantinomatous craniopharyngiomas.
Gomes DC; Jamra SA; Leal LF; Colli LM; Campanini ML; Oliveira RS; Martinelli CE; Elias PC; Moreira AC; Machado HR; Saggioro F; Neder L; Castro M; Antonini SR
Eur J Endocrinol; 2015 May; 172(5):603-8. PubMed ID: 25693592
[TBL] [Abstract][Full Text] [Related]
6. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
[TBL] [Abstract][Full Text] [Related]
7. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A
Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123
[TBL] [Abstract][Full Text] [Related]
8. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma.
Martinez-Barbera JP
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):721-32. PubMed ID: 25611703
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma.
Andoniadou CL; Gaston-Massuet C; Reddy R; Schneider RP; Blasco MA; Le Tissier P; Jacques TS; Pevny LH; Dattani MT; Martinez-Barbera JP
Acta Neuropathol; 2012 Aug; 124(2):259-71. PubMed ID: 22349813
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapies in the medical management of craniopharyngioma.
Iglesias P
Pituitary; 2022 Jun; 25(3):383-392. PubMed ID: 35301645
[TBL] [Abstract][Full Text] [Related]
11. SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma.
Carreno G; Boult JKR; Apps J; Gonzalez-Meljem JM; Haston S; Guiho R; Stache C; Danielson LS; Koers A; Smith LM; Virasami A; Panousopoulos L; Buchfelder M; Jacques TS; Chesler L; Robinson SP; Martinez-Barbera JP
Endocr Relat Cancer; 2019 Mar; 26(3):355-366. PubMed ID: 30645190
[TBL] [Abstract][Full Text] [Related]
12. Contemporary Biological Insights and Clinical Management of Craniopharyngioma.
Apps JR; Muller HL; Hankinson TC; Yock TI; Martinez-Barbera JP
Endocr Rev; 2023 May; 44(3):518-538. PubMed ID: 36574377
[TBL] [Abstract][Full Text] [Related]
13. Craniopharyngioma: a roadmap for scientific translation.
Gupta S; Bi WL; Giantini Larsen A; Al-Abdulmohsen S; Abedalthagafi M; Dunn IF
Neurosurg Focus; 2018 Jun; 44(6):E12. PubMed ID: 29852761
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional analyses of adult and pediatric adamantinomatous craniopharyngioma reveals similar expression signatures regarding potential therapeutic targets.
Prince E; Whelan R; Donson A; Staulcup S; Hengartner A; Vijmasi T; Agwu C; Lillehei KO; Foreman NK; Johnston JM; Massimi L; Anderson RCE; Souweidane MM; Naftel RP; Limbrick DD; Grant G; Niazi TN; Dudley R; Kilburn L; Jackson EM; Jallo GI; Ginn K; Smith A; Chern JJ; Lee A; Drapeau A; Krieger MD; Handler MH; Hankinson TC;
Acta Neuropathol Commun; 2020 May; 8(1):68. PubMed ID: 32404202
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy.
Martinez-Gutierrez JC; D'Andrea MR; Cahill DP; Santagata S; Barker FG; Brastianos PK
Neurosurg Focus; 2016 Dec; 41(6):E2. PubMed ID: 27903124
[TBL] [Abstract][Full Text] [Related]
16. Adamantinomatous craniopharyngioma: pathology, molecular genetics and mouse models.
Martinez-Barbera JP; Buslei R
J Pediatr Endocrinol Metab; 2015 Jan; 28(1-2):7-17. PubMed ID: 25503464
[TBL] [Abstract][Full Text] [Related]
17. Biological Behaviour of Craniopharyngiomas.
Martinez-Barbera JP; Andoniadou CL
Neuroendocrinology; 2020; 110(9-10):797-804. PubMed ID: 32126562
[TBL] [Abstract][Full Text] [Related]
18. Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma.
Kato K; Nakatani Y; Kanno H; Inayama Y; Ijiri R; Nagahara N; Miyake T; Tanaka M; Ito Y; Aida N; Tachibana K; Sekido K; Tanaka Y
J Pathol; 2004 Jul; 203(3):814-21. PubMed ID: 15221941
[TBL] [Abstract][Full Text] [Related]
19. Transcription Factor GLI1 Induces IL-6-Mediated Inflammatory Response and Facilitates the Progression of Adamantinomatous Craniopharyngioma.
Zhao J; Yang Y; Pan Y; Zhou P; Wang J; Zheng Y; Zhang X; Zhai S; Zhang X; Li L; Yang D
ACS Chem Neurosci; 2023 Sep; 14(18):3347-3356. PubMed ID: 37691264
[TBL] [Abstract][Full Text] [Related]
20. Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma.
Donson AM; Apps J; Griesinger AM; Amani V; Witt DA; Anderson RCE; Niazi TN; Grant G; Souweidane M; Johnston JM; Jackson EM; Kleinschmidt-DeMasters BK; Handler MH; Tan AC; Gore L; Virasami A; Gonzalez-Meljem JM; Jacques TS; Martinez-Barbera JP; Foreman NK; Hankinson TC;
J Neuropathol Exp Neurol; 2017 Sep; 76(9):779-788. PubMed ID: 28859336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
